13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001631134
Total reported value
$1.9B
$1.9B
59 檔
34.5%
As reported in its official Q3 2025 Form 13F filing, Sofinnova Investments, Inc.'s tracked investment portfolio stood at $1.9B with 59 total positions.
Sofinnova Investments, Inc. executed strategic sector rebalancing during Q3 2025, establishing 23 new positions while fully exiting 26 holdings and trimming 18 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | Stock-Healthcare | 13.65% | +9.98% | — | |
| 2 | GILD | Gilead Sciences Inc | Stock-Healthcare | 7.60% | +2.24% | NEW | |
| 3 | UTHR | United Therapeutics CORP | Stock-Healthcare | 6.60% | -3.28% | +142.78% | |
| 4 | VERA | Vera Therapeutics Inc | Stock-Other | 4.44% | +1.93% | — | |
| 5 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 4.24% | +0.25% | -15.17% | |
| 6 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 3.46% | — | +180.57% | |
| 7 | RAPP | Rapport Therapeutics Inc | Stock-Other | 3.16% | +1.84% | -2.41% | |
| 8 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.04% | — | +32.06% | |
| 9 | QURE | uniQure N.V. | Stock-Other | 2.99% | — | -39.88% | |
| 10 | DXCM | Dexcom Inc | Stock-Healthcare | 2.87% | -0.94% | EXIT | |
| 11 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.71% | +0.82% | NEW | |
| 12 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 2.61% | -0.62% | +320.36% | |
| 13 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 2.61% | -0.50% | EXIT | |
| 14 | IBB | Ishares Biotechnology ETF | ETF-Tech | 2.57% | -3.05% | EXIT | |
| 15 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.52% | — | — | |
| 16 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.36% | -1.15% | EXIT | |
| 17 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 2.19% | -5.10% | EXIT | |
| 18 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.09% | — | +49.78% | |
| 19 | ABBV | Abbvie Inc | Stock-Healthcare | 1.91% | — | -43.21% | |
| 20 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.71% | +1.56% | — | |
| 21 | COGT | Cogent Biosciences Inc | Stock-Other | 1.67% | -1.02% | -29.43% | |
| 22 | GKOS | Glaukos CORP | Stock-Healthcare | 1.40% | — | — | |
| 23 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.37% | +0.35% | -57.04% | |
| 24 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.36% | +0.85% | -69.55% | |
| 25 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.23% | — | -13.70% | |
| 26 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.23% | — | +642.21% | |
| 27 | EXK | Exact Sciences CORP | Stock-Materials | 1.09% | — | +75.23% | |
| 28 | ✓ | Immatics NV | Stock-Other | 1.04% | +0.56% | -0.57% | |
| 29 | SMMT | Summit Therapeutics Inc | Stock-Other | 1.02% | — | +28.57% | |
| 30 | PHVS | Pharvaris N.V. | Stock-Other | 1.01% | +0.70% | +26.36% | |
| 31 | SUPN | Supernus Pharmaceuticals Inc | Stock-Healthcare | 0.99% | +0.62% | -52.82% | |
| 32 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.91% | +0.75% | +0.51% | |
| 33 | ✓ | Merus N V | Stock-Other | 0.86% | — | -58.79% | |
| 34 | INSM | Insmed Inc | Stock-Healthcare | 0.82% | -1.28% | -66.76% | |
| 35 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.81% | +0.44% | -37.90% | |
| 36 | BIOA | Bioage Labs Inc | Stock-Other | 0.74% | +1.39% | -0.48% | |
| 37 | CELC | Celcuity Inc | Stock-Other | 0.68% | -2.89% | EXIT | |
| 38 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.68% | +0.77% | +60.33% | |
| 39 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 0.63% | — | -50.28% | |
| 40 | GEHC | GE Healthcare Technology | Stock-Healthcare | 0.62% | — | — | |
| 41 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.61% | -0.02% | EXIT | |
| 42 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.50% | -0.67% | +999.66% | |
| 43 | SVRA | Savara Inc | Stock-Other | 0.47% | +0.04% | -1.21% | |
| 44 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.46% | +0.34% | -27.43% | |
| 45 | ANAB | Anaptysbio Inc | Stock-Other | 0.43% | +1.20% | -75.37% | |
| 46 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.39% | -0.51% | EXIT | |
| 47 | NKTR | Nektar Therapeutics | Stock-Other | 0.37% | +0.31% | — | |
| 48 | LQDA | Liquidia CORP | Stock-Other | 0.31% | -0.72% | EXIT | |
| 49 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.28% | — | -84.56% | |
| 50 | IMNM | Immunome Inc | Stock-Other | 0.28% | +0.47% | -43.99% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GILD | Gilead Sciences Inc | +4.5% | +19.23% | Add |
| 2 | QURE | uniQure N.V. | +2.6% | -39.88% | Add |
| 3 | ISRG | Intuitive Surgical Inc | +2.3% | +56.98% | Add |
| 4 | RAPP | Rapport Therapeutics Inc | +1.9% | -2.41% | Trim |
| 5 | ROIV | Roivant Sciences Ltd. | +1.8% | -22.98% | Add |
| 6 | RNAGBP | Avidity Biosciences Inc | +1.4% | +49.78% | Add |
| 7 | AXSM | Axsome Therapeutics Inc | +1.3% | +320.36% | Add |
| 8 | DXCM | Dexcom Inc | +1.1% | +48.87% | Add |
| 9 | COGT | Cogent Biosciences Inc | +0.8% | -29.43% | Trim |
| 10 | BBIO | Bridgebio Pharma Inc | +0.7% | -16.24% | Add |
| 11 | ✓ | Immatics NV | +0.6% | -0.57% | Add |
| 12 | PHVS | Pharvaris N.V. | +0.4% | +26.36% | Add |
| 13 | RCUS | Arcus Biosciences Inc | +0.4% | +0.51% | Add |
| 14 | DYN | Dyne Therapeutics Inc | +0.2% | +60.33% | Add |
| 15 | INBX | Inhibrx Biosciences Inc | +0.2% | -37.90% | Trim |
| 16 | BIOA | Bioage Labs Inc | +0.2% | -0.48% | Trim |
| 17 | PRAX | Praxis Precision Medicines I | +0.1% | +999.66% | Add |
| 18 | JAZZ | Jazz Pharmaceuticals plc | +0.1% | -15.17% | Add |
| 19 | VERA | Vera Therapeutics Inc | +0.1% | — | Unchanged |
| 20 | IRON | Disc Medicine Inc | 0% | +85.35% | Add |
| 21 | ✓ | Establishment Labs Holdings In | -0.1% | -61.64% | Trim |
| 22 | IMNM | Immunome Inc | -0.1% | -43.99% | Trim |
| 23 | AKRO | Akero Therapeutics Inc | -0.1% | -13.70% | Trim |
| 24 | SUPN | Supernus Pharmaceuticals Inc | -0.1% | -52.82% | Trim |
| 25 | SRRK | Scholar Rock Holding CORP | -0.2% | +18.80% | Trim |
| 26 | RYTM | Rhythm Pharmaceuticals Inc | -0.2% | -69.55% | Trim |
| 27 | AVBP | Arrivent Biopharma Inc | -0.3% | — | Unchanged |
| 28 | EWTX | Edgewise Therapeutics Inc | -0.5% | -27.43% | Trim |
| 29 | ACAD | Acadia Pharmaceuticals Inc | -0.5% | — | Trim |
| 30 | SVRA | Savara Inc | -0.5% | -1.21% | Trim |
| 31 | NTRA | Natera Inc | -0.7% | — | Unchanged |
| 32 | INSM | Insmed Inc | -0.7% | -66.76% | Trim |
| 33 | ANAB | Anaptysbio Inc | -1% | -75.37% | Trim |
| 34 | PTCT | Ptc Therapeutics Inc | -1.3% | -50.28% | Trim |
| 35 | IDYA | Ideaya Biosciences Inc | -1.4% | -57.04% | Trim |
| 36 | SLNOEUR | Soleno Therapeutics Inc | -4.1% | -59.95% | Trim |
| 37 | UTHR | United Therapeutics CORP | — | NEW | New buy |
| 38 | SYK | Stryker CORP | — | EXIT | Sold out |
| 39 | QQQ | Invesco Qqq Trust Series 1 | — | EXIT | Sold out |
| 40 | IWM | Ishares Russell 2000 ETF | — | EXIT | Sold out |
| 41 | AZNN | Astrazeneca Plc-spons Adr | — | NEW | New buy |
| 42 | BSX | Boston Scientific CORP | — | NEW | New buy |
| 43 | MDT | Medtronic plc | — | EXIT | Sold out |
| 44 | ALNY | Alnylam Pharmaceuticals Inc | — | EXIT | Sold out |
| 45 | IBB | Ishares Biotechnology ETF | — | NEW | New buy |
| 46 | VRTX | Vertex Pharmaceuticals Inc | — | NEW | New buy |
| 47 | LLY | Eli Lilly & Co | — | EXIT | Sold out |
| 48 | XBI | Ss Spdr S&p Biotech ETF | — | NEW | New buy |
| 49 | ABBV | Abbvie Inc | — | NEW | New buy |
| 50 | SNDX | Syndax Pharmaceuticals Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Sofinnova Investments, Inc. reported a total U.S. public equity portfolio value of $1.9B across 59 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NTRA, GILD, UTHR) accounted for 34.5% of total reported equity market value during Q3 2025.
Top New Position Initiated
UTHR
市值: $120.6M
Top Position Liquidated / Trimmed
SYK
前期市值: $111.1M
During Q3 2025, Sofinnova Investments, Inc.'s top holdings by market value included NTRA (13.7%)、GILD (7.6%)、UTHR (6.6%). The largest single position, NTRA, represented 13.7% of total portfolio value.
In Q3 2025, Sofinnova Investments, Inc. made 82 total portfolio adjustments, initiating 23 new buys, adding to 15 positions, trimming 18 holdings, and fully liquidating 26 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.